Actively Recruiting
Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study
Led by Linkoeping University · Updated on 2026-02-27
240
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The overall aim of this project is to evaluate the effects of a digital support program for patients with heart failure through a cluster-randomized controlled trial, and to investigate the outcomes of different implementation strategies using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance), PRISM (Practical, Robust Implementation and Sustainability Model) and ERIC (Expert Recommendations for Implementing Change) framework. Our primary hypothesis is that the digital support program will improve patients' perceived control over their heart failure, measured with the validated Control Attitude Scale. Secondary hypotheses are that the program will increase patients' health-related quality of life, self-care behaviors, heart failure knowledge, perceived continuity of care, and participation in care, and reduce symptoms of depression. Implementation aim (based on the RE-AIM, PRISM and ERIC frameworks) The implementation component of the study aims to compare two different implementation strategies: a standard (basic) support package versus a tailored, context-specific support strategy. Heart failure clinics at hospitals an within primary care will be matched and randomized into two arms. The intervention arm will receive tailored implementation support to implement the support program. The control arm will recive implementation support according to a predefined standard procedure. Researchers will compare the intervention arm with control arm to see if there are any differences regarding the implementationsuccess between the arms. The patients in both arms will have access to the support program during six months.
CONDITIONS
Official Title
Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with heart failure with reduced ejection fraction (HFrEF) or heart failure with midrange reduced ejection fraction (HFmrEF) (ejection fraction 50%) verified by echocardiography or Magnetic Resonance Imaging
- Access to BankID, a computer, tablet, or smartphone
- Aged 18 years
- Able to understand and communicate in Swedish
- Provided informed consent
You will not qualify if you...
- Barriers to participation such as not being Swedish-speaking, cognitive impairment, severe mental illness, or substance abuse
- Life expectancy of less than six months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Linköping University Hospital
Linköping, Östergötland County, Sweden, 581 85
Actively Recruiting
Research Team
A
Anna Stroemberg, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here